Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

BIMEKIZUMAB

All strengths: Limited Use — Reason for Use code 641 required; same patient cost rules

Shared coverage and patient cost rules
StatusLimited Use — Reason for Use code 641 required
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (L04AC) — coverage varies; not interchangeable

  • Brodalumab (Siliq): limited Use 553
  • Guselkumab (Tremfya One-Press): limited Use 658
  • Ixekizumab (Taltz): limited Use 526
  • Risankizumab (Skyrizi): limited Use 574
  • Secukinumab (Cosentyx): limited Use 476
  • Tildrakizumab (Ilumya): limited Use 629

Bimzelx · DIN 02525275 · 160mg/mL · injection solution-1mL Pref Autoinj (Preservative-Free)

Limited Use — Reason for Use code 641 requiredMarketed · checked 2026-09-02
Write on scriptLU code 641 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 641
Reason for Use code 641 For the treatment of severe (see Note 1 below) plaque psoriasis in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies (see Note 2 below). Claims for the first 6 months must be written by a dermatologist. Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required. Patients not responding adequately at 12 weeks should have treatment discontinued. Note 1: Definition of severe plaque psoriasis: - Body Surface Area (BSA) involvement of at least 10%, or involvement of the face, hands, feet or genital regions, AND - Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND - Dermatology Life Quality Index (DLQI) score of at least 10. Note 2: Definition of failure, intolerance or contraindication to adequate trials of standard therapies: - 6 month trial of at least 3 topical agents including vitamin D analogues and steroids, AND - 12 week trial of phototherapy (unless not accessible), AND - 6 month trial of at least 2 systemic, oral agents used alone or in combination - Methotrexate 15-30mg per week - Acitretin (could have been used with phototherapy) - Cyclosporine Maintenance/Renewal: After 3 months of therapy, patients who respond to therapy should have: - at least a 50% reduction in PASI, AND - at least a 50% reduction in BSA involvement, AND - at least a 5 point reduction in DLQI score Approvals will allow for standard dosing for Bimzelx, which is 320mg subcutaneously every 4 weeks for the first 16 weeks, and every 8 weeks thereafter. A dose of 320mg every 4 weeks after the first 16 weeks may be considered in patients with a body weight of 120kg or more who did not achieve a complete skin response. For patients with no improvement after 16 weeks of treatment at the Health Canada approved dose, higher or more frequent doses are not recommended and the physician should consider switching to an alternative biologic agent. Coverage limit: LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Bimzelx · DIN 02525275 Manufacturer: UCB Canada Inc.; listing date 2023-03-31 Health Canada: Marketed since 2022-03-30 · brand BIMZELX · ATC L04AC21 BIMEKIZUMAB · form Solution · route Subcutaneous · ingredients BIMEKIZUMAB 160 MG/ML · company Ucb canada inc · schedule Prescription, Schedule d
Check this DIN again · Health Canada product record

Bimzelx: Formulary list price $1625.0000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1625.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101428 · Verify on the e-Formulary ↗ (DIN 02525275)

Source record
DIN 02525275: Bimzelx Raw flags: sec12=Y, sec3=Y Item: 849200010; group id 870; item number 2104; lccId 00366; manufacturer id UCB Source form: Inj Sol-1mL Pref Autoinj (Preservative-Free); strength: 160mg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1625.0000; ministry $1625.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02525275 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101428
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02525275
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Bimzelx · DIN 02525267 · 160mg/mL · injection, 1 mL pre-filled syringe (preservative-free)

Limited Use — Reason for Use code 641 requiredMarketed · checked 2026-09-02
Write on scriptLU code 641 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 641
Reason for Use code 641 For the treatment of severe (see Note 1 below) plaque psoriasis in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies (see Note 2 below). Claims for the first 6 months must be written by a dermatologist. Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required. Patients not responding adequately at 12 weeks should have treatment discontinued. Note 1: Definition of severe plaque psoriasis: - Body Surface Area (BSA) involvement of at least 10%, or involvement of the face, hands, feet or genital regions, AND - Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND - Dermatology Life Quality Index (DLQI) score of at least 10. Note 2: Definition of failure, intolerance or contraindication to adequate trials of standard therapies: - 6 month trial of at least 3 topical agents including vitamin D analogues and steroids, AND - 12 week trial of phototherapy (unless not accessible), AND - 6 month trial of at least 2 systemic, oral agents used alone or in combination - Methotrexate 15-30mg per week - Acitretin (could have been used with phototherapy) - Cyclosporine Maintenance/Renewal: After 3 months of therapy, patients who respond to therapy should have: - at least a 50% reduction in PASI, AND - at least a 50% reduction in BSA involvement, AND - at least a 5 point reduction in DLQI score Approvals will allow for standard dosing for Bimzelx, which is 320mg subcutaneously every 4 weeks for the first 16 weeks, and every 8 weeks thereafter. A dose of 320mg every 4 weeks after the first 16 weeks may be considered in patients with a body weight of 120kg or more who did not achieve a complete skin response. For patients with no improvement after 16 weeks of treatment at the Health Canada approved dose, higher or more frequent doses are not recommended and the physician should consider switching to an alternative biologic agent. Coverage limit: LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Bimzelx · DIN 02525267 Manufacturer: UCB Canada Inc.; listing date 2023-03-31 Health Canada: Marketed since 2022-03-30 · brand BIMZELX · ATC L04AC21 BIMEKIZUMAB · form Solution · route Subcutaneous · ingredients BIMEKIZUMAB 160 MG/ML · company Ucb canada inc · schedule Schedule d, Prescription
Check this DIN again · Health Canada product record

Bimzelx: Formulary list price $1625.0000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1625.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101427 · Verify on the e-Formulary ↗ (DIN 02525267)

Source record
DIN 02525267: Bimzelx Raw flags: sec12=Y, sec3=Y Item: 849200011; group id 870; item number 2105; lccId 00366; manufacturer id UCB Source form: Inj Sol-1mL Pref Syr (Preservative-Free); strength: 160mg/mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1625.0000; ministry $1625.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02525267 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101427
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02525267
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Bimzelx · DIN 02553627 · 320mg/2mL · injection solution-2mL Pref Autoinj (Preservative-Free)

Limited Use — Reason for Use code 641 requiredMarketed · checked 2026-09-02
Write on scriptLU code 641 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 641
Reason for Use code 641 For the treatment of severe (see Note 1 below) plaque psoriasis in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies (see Note 2 below). Claims for the first 6 months must be written by a dermatologist. Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required. Patients not responding adequately at 12 weeks should have treatment discontinued. Note 1: Definition of severe plaque psoriasis: - Body Surface Area (BSA) involvement of at least 10%, or involvement of the face, hands, feet or genital regions, AND - Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND - Dermatology Life Quality Index (DLQI) score of at least 10. Note 2: Definition of failure, intolerance or contraindication to adequate trials of standard therapies: - 6 month trial of at least 3 topical agents including vitamin D analogues and steroids, AND - 12 week trial of phototherapy (unless not accessible), AND - 6 month trial of at least 2 systemic, oral agents used alone or in combination - Methotrexate 15-30mg per week - Acitretin (could have been used with phototherapy) - Cyclosporine Maintenance/Renewal: After 3 months of therapy, patients who respond to therapy should have: - at least a 50% reduction in PASI, AND - at least a 50% reduction in BSA involvement, AND - at least a 5 point reduction in DLQI score Approvals will allow for standard dosing for Bimzelx, which is 320mg subcutaneously every 4 weeks for the first 16 weeks, and every 8 weeks thereafter. A dose of 320mg every 4 weeks after the first 16 weeks may be considered in patients with a body weight of 120kg or more who did not achieve a complete skin response. For patients with no improvement after 16 weeks of treatment at the Health Canada approved dose, higher or more frequent doses are not recommended and the physician should consider switching to an alternative biologic agent. Coverage limit: LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Bimzelx · DIN 02553627 Manufacturer: UCB Canada Inc.; listing date 2025-08-29 Health Canada: Marketed since 2025-04-07 · brand BIMZELX · ATC L04AC21 BIMEKIZUMAB · form Solution · route Subcutaneous · ingredients BIMEKIZUMAB 320 MG/2ML · company Ucb canada inc · schedule Prescription, Schedule d
Check this DIN again · Health Canada product record

Bimzelx: Formulary list price $3250.0000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $3250.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104254 · Verify on the e-Formulary ↗ (DIN 02553627)

Source record
DIN 02553627: Bimzelx Raw flags: sec12=Y, sec3=Y Item: 849200015; group id 870; item number 2106; lccId 00366; manufacturer id UCB Source form: Inj Sol-2mL Pref Autoinj (Preservative-Free); strength: 320mg/2mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $3250.0000; ministry $3250.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02553627 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104254
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02553627
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Bimzelx · DIN 02553619 · 320mg/2mL · injection, 2 mL pre-filled syringe (preservative-free)

Limited Use — Reason for Use code 641 requiredMarketed · checked 2026-09-02
Write on scriptLU code 641 (patient must meet the criteria below)
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 641
Reason for Use code 641 For the treatment of severe (see Note 1 below) plaque psoriasis in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies (see Note 2 below). Claims for the first 6 months must be written by a dermatologist. Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required. Patients not responding adequately at 12 weeks should have treatment discontinued. Note 1: Definition of severe plaque psoriasis: - Body Surface Area (BSA) involvement of at least 10%, or involvement of the face, hands, feet or genital regions, AND - Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND - Dermatology Life Quality Index (DLQI) score of at least 10. Note 2: Definition of failure, intolerance or contraindication to adequate trials of standard therapies: - 6 month trial of at least 3 topical agents including vitamin D analogues and steroids, AND - 12 week trial of phototherapy (unless not accessible), AND - 6 month trial of at least 2 systemic, oral agents used alone or in combination - Methotrexate 15-30mg per week - Acitretin (could have been used with phototherapy) - Cyclosporine Maintenance/Renewal: After 3 months of therapy, patients who respond to therapy should have: - at least a 50% reduction in PASI, AND - at least a 50% reduction in BSA involvement, AND - at least a 5 point reduction in DLQI score Approvals will allow for standard dosing for Bimzelx, which is 320mg subcutaneously every 4 weeks for the first 16 weeks, and every 8 weeks thereafter. A dose of 320mg every 4 weeks after the first 16 weeks may be considered in patients with a body weight of 120kg or more who did not achieve a complete skin response. For patients with no improvement after 16 weeks of treatment at the Health Canada approved dose, higher or more frequent doses are not recommended and the physician should consider switching to an alternative biologic agent. Coverage limit: LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Bimzelx · DIN 02553619 Manufacturer: UCB Canada Inc.; listing date 2025-08-29 Health Canada: Marketed since 2025-04-07 · brand BIMZELX · ATC L04AC21 BIMEKIZUMAB · form Solution · route Subcutaneous · ingredients BIMEKIZUMAB 320 MG/2ML · company Ucb canada inc · schedule Schedule d, Prescription
Check this DIN again · Health Canada product record

Bimzelx: Formulary list price $3250.0000/unit (unit not stated in source; not the patient's cost)

Ministry pays: $3250.0000 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104253 · Verify on the e-Formulary ↗ (DIN 02553619)

Source record
DIN 02553619: Bimzelx Raw flags: sec12=Y, sec3=Y Item: 849200014; group id 870; item number 2107; lccId 00366; manufacturer id UCB Source form: Inj Sol-2mL Pref Syr (Preservative-Free); strength: 320mg/2mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $3250.0000; ministry $3250.0000 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02553619 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104253
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02553619
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (84:00 SKIN AND MUCOUS MEMBRANE PREPARATIONS) and how they are covered

Matched class: 84:00 SKIN AND MUCOUS MEMBRANE PREPARATIONS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ACITRETIN, AZELAIC ACID, BECLOMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE IN A BASE CONTAINING PROPYLENE GLYCOL, BETAMETHASONE DIPROPIONATE IN PROPYLENE GLYCOL BASE, CALCIPOTRIOL & BETAMETHASONE DIPROPIONATE, CLINDAMYCIN PHOSPHATE & BENZOYL PEROXIDE, DIMETHICONE., FLUOROURACIL, FUSIDIC ACID, HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE & TAZAROTENE, ISOPROPYL MYRISTATE, ISOTRETINOIN, METRONIDAZOLE & NYSTATIN, MICONAZOLE NITRATE, MOMETASONE FUROATE, MUPIROCIN CALCIUM, PERMETHRIN, PYRETHRINS & PIPERONYL BUTOXIDE, SILVER SULFADIAZINE, SODIUM FUSIDATE, TERBINAFINE HCL, ZINC SULFATE Some products covered without a code (check the product listing): AMCINONIDE, BETAMETHASONE DIPROPIONATE, BETAMETHASONE VALERATE, CLOBETASOL PROPIONATE, CLOTRIMAZOLE, COLLAGENASE, DESONIDE, FLUOCINONIDE, HYDROCORTISONE, HYDROCORTISONE ACETATE, HYDROCORTISONE VALERATE, KETOCONAZOLE, METRONIDAZOLE, MUPIROCIN, NYSTATIN, TERCONAZOLE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE 0.1% IN ORABASE 84:00 SKIN AND MUCOUS MEMBRANE PREPARATIONS

GUSELKUMAB

· 2 products · Limited Use, codes 658 · strengths: 100mg/mL · Inj Sol-1mL Autoinj (Preservative-Free), Inj Sol-1mL Pref Syr (Preservative-Free)

TILDRAKIZUMAB

· 1 products · Limited Use, codes 629 · strengths: 100mg/mL · Inj Sol-1mL Pref Syr (Preservative-Free)

HALOBETASOL PROPIONATE & TAZAROTENE

· 1 products · General benefit · strengths: 0.01% & 0.045% · Lot

TAZAROTENE

· 1 products · Limited Use, codes 636 · strengths: 0.045% w/w · Lot

ACYCLOVIR

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5% · Top Oint Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 84:00 84:04:04 Antibiotics

CLINDAMYCIN PHOSPHATE & BENZOYL PEROXIDE

· 4 products · General benefit · strengths: 1% & 5% · Gel, Top Gel

FUSIDIC ACID

· 2 products · General benefit · strengths: 2% · Cr

MUPIROCIN

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 2% · Oint

MUPIROCIN CALCIUM

· 1 products · General benefit · strengths: 2% w/w · Cr

SODIUM FUSIDATE

· 2 products · General benefit · strengths: 2% · Oint

CLINDAMYCIN PHOSPHATE & ADAPALENE & BENZOYL PEROXIDE

· 1 products · Limited Use, codes 724 · strengths: 1.2% w/w & 0.15% w/w & 3.1% w/w · Top Gel Pump

CLINDAMYCIN

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1% · Top Sol Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 84:04:04 and 53 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: hidradenitis suppurativa, psoriasis, psoriatic arthritis
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: ACITRETIN METHOTREXATE · General benefit (29), Listed, not a benefit (1), Off-Formulary Interchangeable, not an ODB benefit (4) • Severe disabling psoriasis/psoriatic arthritis PM: https://pdf.hres.ca/dpd_pm/00078227.PDF; date JAN 08, 2025; DIN 02170698; fetched 2026-09-10 Product monograph SECUKINUMAB · Limited Use, codes 476 Indications COSENTYX® (secukinumab injection/secukinumab for injection) is indicated for: Adult patients Plaque psoriasis COSENTYX is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. PM: https://pdf.hres.ca/dpd_pm/00080972.PDF; date not captured; DIN 02529653; fetched 2026-09-10 Product monograph Hidradenitis Suppurativa COSENTYX is indicated for the treatment of adult patients with moderate to severe hidradenitis suppurativa (acne inversa) who have responded inadequately to conventional systemic hidradenitis suppurativa therapy (see 14.1.5 Hidradenitis suppurativa). 1.1 Pediatrics Plaque psoriasis COSENTYX (secukinumab injection/secukinumab for injection) is indicated for the treatment of moderate to severe plaque psoriasis in patients 6 year and older who are candidates for systemic therapy or phototherapy. PM: https://pdf.hres.ca/dpd_pm/00080972.PDF; date not captured; DIN 02529653; fetched 2026-09-10 Product monograph ACITRETIN · General benefit 1 INDICATIONS SORIATANE (acitretin) is indicated for: • Severe psoriasis (includes erythrodermic and pustular types) • Other disorders of keratinization Severe psoriasis is a condition that involves more than 10% of body surface area or is physically, occupationally or psychologically disabling. PM: https://pdf.hres.ca/dpd_pm/00080165.PDF; date APR 04, 2025; DIN 02070847; fetched 2026-09-10 Product monograph APREMILAST · Off-Formulary Interchangeable, not an ODB benefit Indications • Plaque Psoriasis OTEZLA (apremilast) is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. PM: https://pdf.hres.ca/dpd_pm/00084256.PDF; date 2026-04-10; DIN 02434318; fetched 2026-09-10 Product monograph CYCLOSPORINE · Off-Formulary Interchangeable, not an ODB benefit (2), General benefit (8) Psoriasis NEORAL capsules and oral solution (cyclosporine) are indicated for the treatment of severe psoriasis in patients for whom conventional therapy is ineffective or inappropriate. PM: https://pdf.hres.ca/dpd_pm/00085584.PDF; date 2026-07-30; DIN 02150662; fetched 2026-09-10 Product monograph ETANERCEPT · Limited Use, codes 512, 513, 514, 563, 591 (3), Limited Use, codes 498, 499, 514, 563, 591 (4) • treatment of adult patients with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy. PM: https://pdf.hres.ca/dpd_pm/00083562.PDF; date August 31, 2016; DIN 02455323; fetched 2026-09-10 Product monograph INFLIXIMAB · Limited Use, codes 468, 469, 470, 471, 477, 478, 479 (2), Limited Use, codes 541, 542, 543, 544, 545, 546, 547 (1), Limited Use, codes 715, 716, 718 (2), Limited Use, codes 592, 593, 594, 595, 596, 597, 598 (1) • treatment of adult patients with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy. For patients with chronic moderate plaque psoriasis, RemdantryTM should be used after phototherapy has been shown to be ineffective or inappropriate. When assessing the severity of psoriasis, the health professional should consider the extent of involvement, location of lesions, response to previous treatments, and impact of disease on the patient’s PM: https://pdf.hres.ca/dpd_pm/00081840.PDF; date September 2, 2025; DIN 02419475; fetched 2026-09-10 Product monograph RISANKIZUMAB · Limited Use, codes 574 Indications SKYRIZI (risankizumab injection) is indicated for: • the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. PM: https://pdf.hres.ca/dpd_pm/00085642.PDF; date 2026-07-08; DIN 02519283; fetched 2026-09-10 Product monograph USTEKINUMAB · Limited Use, codes 669, 670, 671, 672 (5), Limited Use, codes 668, 669, 671, 672 (6), Limited Use, codes 669, 671, 672, 733 (3), Limited Use, codes 669, 671, 672, 742 (2), Limited Use, codes 671, 672 (4) Plaque Psoriasis JAMTEKI (ustekinumab) is indicated for: • the treatment of chronic moderate to severe plaque psoriasis in adult patients who are candidates for phototherapy or systemic therapy. PM: https://pdf.hres.ca/dpd_pm/00077781.PDF; date November 9, 2023; DIN 02543036; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1. Indications Bimzelx (bimekizumab injection) is indicated for: • Psoriasis (PsO) The treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. • Psoriatic arthritis (PsA) The treatment of adult patients with active psoriatic arthritis. Bimzelx can be used alone or in combination with a conventional non-biologic disease-modifying antirheumatic drug (cDMARD) (e.g., methotrexate). • Axial Spondyloarthritis (axSpA) Ankylosing Spondylitis (AS, radiographic spondyloarthritis) The treatment of adult patients with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy. Non-radiographic axial spondyloarthritis (nr-axSpA) The treatment of adult patients with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately or are intolerant to nonsteroidal anti- inflammatory drugs (NSAIDs). • Hidradenitis suppurativa (HS) The treatment of adult patients with moderate to sever… https://pdf.hres.ca/dpd_pm/00082779.PDF PM date: 2025-12-12 Source product: BIMZELX; DIN 02525267; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.